FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089677152> ?p ?o ?g. }

• W3089677152 endingPage "966" @default.
• W3089677152 startingPage "953" @default.
• W3089677152 abstract "Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU). This a priori, exploratory, secondary analysis from the ASPECT-NP clinical trial evaluated resource utilization among patients with ventilated HABP (vHABP)/VABP treated with ceftolozane/tazobactam or meropenem. This analysis used data from the randomized, double-blind, noninferiority phase 3 ASPECT-NP trial of patients with vHABP/VABP randomized to receive ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g) or meropenem 1 g for 8–14 days. Day 28 outcomes included hospital length of stay (LOS), intensive care unit (ICU) LOS, and time to mechanical ventilation extubation in the microbiological intention-to-treat (mITT) population and in an HCRU population. The HCRU population, a subset of patients from the mITT population that were alive at day 28, was used to remove resource use bias influenced by mortality rates. Ceftolozane/tazobactam-treated versus meropenem-treated patients, respectively, had fewer deaths (20.1% vs. 25.5%), fewer hospital discharges (30.7% vs. 32.4%), and higher ICU discharges (60.0% vs. 58.3%) and extubations (51.9% vs. 48.2%) by day 28. In the HCRU population, adjusted LOS differences (95% confidence intervals) for ceftolozane/tazobactam compared with meropenem were 0.1 (− 1.4 to 1.6) hospitalization days, − 1.4 (− 2.9 to 0.2) ICU days, and − 0.9 (− 2.4 to 0.7) mechanical ventilation days. Patterns were similar among the VABP and Pseudomonas aeruginosa subgroups. Similar 28-day resource utilization outcomes were observed between ceftolozane/tazobactam and meropenem in the mITT population of patients from ASPECT-NP with vHABP/VABP due to gram-negative pathogens. ASPECT-NP was not powered to detect differences in resource utilization outcomes between treatment groups; however, numerical differences in ICU LOS and duration of mechanical ventilation were noted. Further study is needed to assess resource utilization in the real-world practice setting, especially among patients excluded from ASPECT-NP, including those with resistant P. aeruginosa infections. ClinicalTrials.gov: NCT02070757, registered February 25, 2014; EudraCT: 2012-002862-11." @default.
• W3089677152 created "2020-10-08" @default.
• W3089677152 creator A5009305511 @default.
• W3089677152 creator A5020813351 @default.
• W3089677152 creator A5026604447 @default.
• W3089677152 creator A5071303931 @default.
• W3089677152 creator A5084249121 @default.
• W3089677152 date "2020-09-30" @default.
• W3089677152 modified "2023-10-14" @default.
• W3089677152 title "Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial" @default.
• W3089677152 cites W1529736910 @default.
• W3089677152 cites W1906880034 @default.
• W3089677152 cites W1965493147 @default.
• W3089677152 cites W1984024012 @default.
• W3089677152 cites W1989886020 @default.
• W3089677152 cites W1995976516 @default.
• W3089677152 cites W2027003617 @default.
• W3089677152 cites W2036924892 @default.
• W3089677152 cites W2095687971 @default.
• W3089677152 cites W2096988592 @default.
• W3089677152 cites W2105939831 @default.
• W3089677152 cites W2123793178 @default.
• W3089677152 cites W2124161201 @default.
• W3089677152 cites W2140353364 @default.
• W3089677152 cites W2473016454 @default.
• W3089677152 cites W2547414132 @default.
• W3089677152 cites W2568826445 @default.
• W3089677152 cites W2804153703 @default.
• W3089677152 cites W2810740591 @default.
• W3089677152 cites W2884201768 @default.
• W3089677152 cites W2899956318 @default.
• W3089677152 cites W2900555106 @default.
• W3089677152 cites W2902385366 @default.
• W3089677152 cites W2951980590 @default.
• W3089677152 cites W2975920332 @default.
• W3089677152 cites W4230357700 @default.
• W3089677152 cites W846546774 @default.
• W3089677152 doi "https://doi.org/10.1007/s40121-020-00343-0" @default.
• W3089677152 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7524640" @default.
• W3089677152 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32996064" @default.
• W3089677152 hasPublicationYear "2020" @default.
• W3089677152 type Work @default.
• W3089677152 sameAs 3089677152 @default.
• W3089677152 citedByCount "3" @default.
• W3089677152 countsByYear W30896771522021 @default.
• W3089677152 countsByYear W30896771522022 @default.
• W3089677152 countsByYear W30896771522023 @default.
• W3089677152 crossrefType "journal-article" @default.
• W3089677152 hasAuthorship W3089677152A5009305511 @default.
• W3089677152 hasAuthorship W3089677152A5020813351 @default.
• W3089677152 hasAuthorship W3089677152A5026604447 @default.
• W3089677152 hasAuthorship W3089677152A5071303931 @default.
• W3089677152 hasAuthorship W3089677152A5084249121 @default.
• W3089677152 hasBestOaLocation W30896771521 @default.
• W3089677152 hasConcept C126322002 @default.
• W3089677152 hasConcept C168563851 @default.
• W3089677152 hasConcept C177713679 @default.
• W3089677152 hasConcept C194828623 @default.
• W3089677152 hasConcept C2776376669 @default.
• W3089677152 hasConcept C2776710477 @default.
• W3089677152 hasConcept C2777080012 @default.
• W3089677152 hasConcept C2777184939 @default.
• W3089677152 hasConcept C2777637488 @default.
• W3089677152 hasConcept C2777914695 @default.
• W3089677152 hasConcept C2778193466 @default.
• W3089677152 hasConcept C2778266534 @default.
• W3089677152 hasConcept C2779375183 @default.
• W3089677152 hasConcept C2908647359 @default.
• W3089677152 hasConcept C501593827 @default.
• W3089677152 hasConcept C523546767 @default.
• W3089677152 hasConcept C54355233 @default.
• W3089677152 hasConcept C71924100 @default.
• W3089677152 hasConcept C86803240 @default.
• W3089677152 hasConcept C89423630 @default.
• W3089677152 hasConcept C94665300 @default.
• W3089677152 hasConcept C99454951 @default.
• W3089677152 hasConceptScore W3089677152C126322002 @default.
• W3089677152 hasConceptScore W3089677152C168563851 @default.
• W3089677152 hasConceptScore W3089677152C177713679 @default.
• W3089677152 hasConceptScore W3089677152C194828623 @default.
• W3089677152 hasConceptScore W3089677152C2776376669 @default.
• W3089677152 hasConceptScore W3089677152C2776710477 @default.
• W3089677152 hasConceptScore W3089677152C2777080012 @default.
• W3089677152 hasConceptScore W3089677152C2777184939 @default.
• W3089677152 hasConceptScore W3089677152C2777637488 @default.
• W3089677152 hasConceptScore W3089677152C2777914695 @default.
• W3089677152 hasConceptScore W3089677152C2778193466 @default.
• W3089677152 hasConceptScore W3089677152C2778266534 @default.
• W3089677152 hasConceptScore W3089677152C2779375183 @default.
• W3089677152 hasConceptScore W3089677152C2908647359 @default.
• W3089677152 hasConceptScore W3089677152C501593827 @default.
• W3089677152 hasConceptScore W3089677152C523546767 @default.
• W3089677152 hasConceptScore W3089677152C54355233 @default.
• W3089677152 hasConceptScore W3089677152C71924100 @default.
• W3089677152 hasConceptScore W3089677152C86803240 @default.
• W3089677152 hasConceptScore W3089677152C89423630 @default.
• W3089677152 hasConceptScore W3089677152C94665300 @default.
• W3089677152 hasConceptScore W3089677152C99454951 @default.

• next